4736 studies found for:    gene therapy[ALL-FIELDS]
Show Display Options
Rank Status Study
21 Completed Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up
Conditions: Chronic Granulomatous Disease;   Communicable Disease
Interventions: Drug: Gene Therapy Method for CGD;   Device: Isolex 300i Magnetic Cell Selector
22 Recruiting Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
Conditions: Severe Combined Immunodeficiency;   Malignancy, Hematologic;   Neuroblastoma;   Neoplasm;   Mucopolysaccharidosis I
Intervention: Procedure: Venipuncture
23 Completed Gene Therapy ADA Deficiency
Condition: Adenosine Deaminase Deficiency
Intervention: Biological: Intravenous infusion of transduced cells
24 Recruiting Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
Conditions: X-linked Severe Combined Immunodeficiency;   XSCID;   SCID-X1;   Gamma C-Deficient SCID
Interventions: Other: Gene-modified CD34+ Hematopoietic stem cells;   Drug: Busulfan
25 Recruiting Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome
Condition: Wiskott-Aldrich Syndrome
Intervention: Biological: Retrovirus-mediated gene transfer
26 Withdrawn Gene Therapy for Prostate Cancer That Returns After Radiation Therapy
Conditions: Prostatic Neoplasms;   Neoplasm Recurrence, Local
Intervention: Genetic: Ad.hIL-12
27 Recruiting Gene Therapy for WAS
Condition: Wiskott-Aldrich Syndrome
Intervention: Genetic: Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene
28 Active, not recruiting ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID
Condition: Immunologic Deficiency Syndromes
Intervention: Genetic: Gene transduced CD34+ cells
29 Completed
Has Results
Randomized Trial of Suicide Gene Therapy and Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: Ad5-yCD/mutTKSR39rep-ADP;   Radiation: IMRT
30 Recruiting Gene Therapy for Wiskott-Aldrich Syndrome (WAS)
Condition: Wiskott-Aldrich Syndrome
Intervention: Genetic: Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene
31 Completed Gene Therapy in Treating Patients With Primary Brain Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: gene therapy;   Drug: chemotherapy;   Drug: ganciclovir;   Procedure: conventional surgery
32 Recruiting Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)
Condition: X-linked Severe Combined Immunodeficiency
Intervention: Genetic: Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
33 Terminated Gene Therapy for Chronic Granulomatous Disease
Condition: Chronic Granulomatous Disease
Intervention: Drug: Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells
34 Recruiting Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B
Condition: Hemophilia B
Intervention: Biological: AskBio009
35 Completed Gene Therapy for Gyrate Atrophy
Condition: Gyrate Atrophy
Intervention: Procedure: Gene therapy
36 Completed Follow-up of Breast Cancer and Multiple Myeloma Patients Previously Enrolled in NIH Gene Therapy Studies
Condition: Gene Transfer
Intervention:
37 Enrolling by invitation Long-term Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy
Conditions: Beta-Thalassemia;   Sickle Cell Disease
Intervention: Other: Safety and efficacy assessments
38 Active, not recruiting Gene Therapy for Metachromatic Leukodystrophy
Condition: Metachromatic Leukodystrophy
Intervention: Genetic: Autologous CD34+ stem cells transduced with ARSA encoding lentiviral vector
39 Terminated Suicide Gene Therapy Trial
Condition: Haploidentical Stem Cell Transplantation
Intervention: Biological: HSVTK retrovirally-transduced donor T lymphocytes
40 Completed Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria
Condition: Acute Intermittent Porphyria
Interventions: Genetic: rAAV2/5-PBGD vector dosage 1;   Genetic: rAAV2/5-PBGD vector dosage 2;   Genetic: rAAV2/5-PBGD vector dosage 3;   Genetic: rAAV2/5-PBGD vector dosage 4

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years